本研究是關於肝細胞癌（ HCC ）患者在肝切除或消融後腫瘤復發風險較高的輔助治療測試的可行性研究。透過在手術過程中收集個別患者的肝臟和腫瘤組織，將採用3D生物列印技術來構建患者特定的仿生肝模型- “Liver-in-Cube” ，以測試和確定對個體最有效的輔助療法
適應症：HCC - Hepatocellular Carcinoma
收案條件
納入條件
- Age ≥ 18 years at the time of screening
- Diagnosis of HCC
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1
- With or without prior locoregional therapy such as transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT) before surgery - Meet any item indicating higher risk of tumour recurrence: any tumour size ≥ 5cm, number of tumour ≥ 3, presence of microvascular or marcovascular invasion, or poor tumour differentiation
- No prior systemic therapy for HCC
- No other active malignancies within 5 years, except malignancies with a negligible risk of metastasis or death (eg. 5-year overall survival rate \> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer
- Willing and able to provide written informed consent for the collection and usage of biological samples
排除條件
- Non-HCC diagnosis, including fibrolamellar HCC, sarcomatoid HCC, mixed HCC cholangiocarcinoma etc.
- Fail to give consent or refusal to take part in the study
- Child-Pugh class C liver cirrhosis
- Receipt of any prior systemic therapy for HCC
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。